Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||DAN-222 + Niraparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DAN-222||DAN 222|DAN222||TOPO1 inhibitor 10||DAN-222 is a polymeric nanoparticle formulation of the topoisomerase I inhibitor camptothecin, which may lead to inhibition of tumor growth (Cancer Res (2022) 82 (4_Supplement): P5-16-16).|
|Niraparib||Zejula||MK4827||PARP Inhibitor (Pan) 25||Zejula (niraparib) binds and inhibits PARP, which may result in accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved as maintenance therapy in patients with recurrent or newly-diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy, and in ovarian, fallopian tube, or primary peritoneal cancer that received 3 or more chemotherapies and is homologous recombination deficient as indicated by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and progressed 6 months or more after response to last platinum-based chemotherapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05261269||Phase I||DAN-222 DAN-222 + Niraparib||A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer||Recruiting||USA||0|